Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans.

Vadim Z Lankin, Galina G Konovalova, Sergey P Domogatsky, Alla K Tikhaze, Igor N Klots, Marat V Ezhov

International journal of molecular sciences 2023 Jun 21

filter terms:

The kinetics of elimination of various dicarbonyl-modified low-density lipoproteins from the bloodstream of Macaca mulatta monkeys were investigated. The low-density lipoproteins (LDL) in the monkey blood plasma were isolated by density gradient ultracentrifugation and labeled in vitro with the fluorescent dye FITC; thereupon, they were modified with different natural low molecular-weight dicarbonyls: malondialdehyde (MDA), glyoxal, or methylglyoxal. The control native FITC-labeled LDL and dicarbonyl-modified FITC-labeled LDL were injected into the monkey's ulnar vein; thereafter, blood samples were taken at fixed time intervals during 24 h. The plasma level of FITC-labeled LDL was determined with spectrofluorimetry. The study established that glyoxal- and monkeysglyoxal-labeled LDL circulated in monkey virtually at the same time as native (non-modified) LDL. In contrast, MDA-modified LDL disappeared from the blood extremely rapidly. Administration of the PCSK9 inhibitor involocumab (which increases LDL utilization) to patients with coronary heart disease (CHD) was found to significantly reduce levels of MDA-modified LDL.

Citation

Vadim Z Lankin, Galina G Konovalova, Sergey P Domogatsky, Alla K Tikhaze, Igor N Klots, Marat V Ezhov. Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans. International journal of molecular sciences. 2023 Jun 21;24(13)